Lilyana Amezcua, MD

Professor of Neurology (Clinical Scholar)

Program Director, Multiple Sclerosis Fellowship

Director, Keck Huntington Beach Multiple Sclerosis Infusion Program

Culture and Engagement Champion

Image of Lilyana Amezcua, MD
Is this your profile? Click to edit

Overview

Dr. Amezcua is an Associate Professor of Neurology and the Division Chief for Neuroimmunology and Multiple Sclerosis at the University of Southern California (USC), Keck School of Medicine. She received her Bachelor of Science degree from the University of California Irvine in Irvine, California, and her medical degree from Jefferson Medical College in Philadelphia, Pennsylvania, followed by neurology residency and clinical fellowship in neuroimmunology and multiple sclerosis at USC. She received her Master of Science degree in clinical, biomedical, and translational science from USC Preventive Medicine under a Clinical Translational Science Institute NIH KL2 award.

She spearheaded the collaborative research consortium: Alliance for Research in Hispanic MS (ARHMS) and serves as principal investigator. ARHMS is geared at better-defining health disparities, by examining modifiable (social determinants of health and environmental) from non-modifiable genetic factors involved in disease severity and progression specific to the Hispanic and Latino population affected with MS. She serves in numerous national and international committees including as an elected member to the NMSS National Medical Advisory Committee (NMAC), American Academy of Neurology Quality Measures for MS, and NIH NINDS Health Disparities Strategic Steering Committee. She has been recognized with numerous awards including the NMSS Health Care Champion.

Awards

  • Consortium of Multiple Sclerosis Centers: Best Platform: Patient and Family Education, 2016
  • American Academy of Neurology: Fellow of the American Academy of Neurology, 2019
  • National Multiple Sclerosis Society: Healthcare Physician Champion Award, 2022

Publications

  • Two Years of Ocrelizumab Treatment in Black and Hispanic People with Multiple Sclerosis in CHIMES: A Single-Arm Clinical Trial. Ann Neurol. 2026 Jul 30.. View in PubMed
  • Tailoring disease-modifying therapy approaches across multiple sclerosis sub-populations. Mult Scler Relat Disord. 2026 Jul 10; 113:107389.. View in PubMed
  • Associations between perfluoroalkyl substances and multiple sclerosis in U.S. cohorts compared with NMOSD, MOGAD, and healthy controls. Environ Res. 2026 Aug 15; 303(Pt 1):124763.. View in PubMed
  • Alliance for research in hispanic multiple sclerosis registry as a facilitator to clinical research participation. Mult Scler Relat Disord. 2026 Jun; 110:107188.. View in PubMed
  • ‘Getting comfortable with the uncomfortable’: barriers, facilitators and influences on reproductive health discussions from Hispanic women with systemic lupus erythematosus in the USA – a qualitative study. Lupus Sci Med. 2026 Mar 24; 13(1).. View in PubMed
  • A novel mutation in colony-stimulating factor 1 receptor (CSF1R) causing CSF1R-related disorder (CSF1R-RD). Neurocase. 2026 Feb; 32(1):13-21.. View in PubMed
  • Alpha Lipoic Acid in Multiple Sclerosis: It’s All in the Details. Neurology. 2026 Jan 13; 106(1):e214578.. View in PubMed
  • Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. 2025 10; 24(10):850-865.. View in PubMed
  • Serum Levels of Aryl Hydrocarbon Receptor Plasma Agonist Activity Are Reduced in Patients With NMOSD and Correlate With Disease Activity. Neurol Neuroimmunol Neuroinflamm. 2025 09; 12(5):e200457.. View in PubMed
  • Multiple Sclerosis in People of Diverse Racial and Ethnic Backgrounds: Presentation, Disease Course, and Interactions with Disease-Modifying Therapy. CNS Drugs. 2025 09; 39(9):823-842.. View in PubMed